ASLAN Pharmaceuticals Ltd (ASLN) Stock Overview
USA - NASDAQ:ASLN - US04522R2004 - ADR
ASLN Key Statistics, Chart & Performance
The current stock price of ASLN is 0.6 USD. In the past month the price decreased by -75.97%. In the past year, price decreased by -97.26%.
ASLN Latest News, Press Relases and Analysis
ASLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Related stock screener links
About ASLN
Company Profile
Aslan Pharmaceuticals Ltd is a SG-based company operating in Biotechnology industry. ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Company Info
ASLAN Pharmaceuticals Ltd
83 Clemenceau Avenue, #12-03 UE Square
Singapore 239920 SG
CEO: Carl Firth
Employees: 34
Phone: 6562224235
ASLAN Pharmaceuticals Ltd / ASLN FAQ
What does ASLAN Pharmaceuticals Ltd do?
Aslan Pharmaceuticals Ltd is a SG-based company operating in Biotechnology industry. ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Can you provide the latest stock price for ASLAN Pharmaceuticals Ltd?
The current stock price of ASLN is 0.6 USD. The price decreased by -14.27% in the last trading session.
Does ASLAN Pharmaceuticals Ltd pay dividends?
ASLN does not pay a dividend.
How is the ChartMill rating for ASLAN Pharmaceuticals Ltd?
ASLN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of ASLAN Pharmaceuticals Ltd (ASLN) based on its PE ratio?
ASLAN Pharmaceuticals Ltd (ASLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.15).
What is the employee count for ASLN stock?
ASLAN Pharmaceuticals Ltd (ASLN) currently has 34 employees.
What is ASLAN Pharmaceuticals Ltd worth?
ASLAN Pharmaceuticals Ltd (ASLN) has a market capitalization of 1.70M USD. This makes ASLN a Nano Cap stock.
ASLN Technical Analysis
ASLN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ASLN. ASLN has a bad profitability rating. Also its financial health evaluation is rather negative.
ASLN Financial Highlights
Over the last trailing twelve months ASLN reported a non-GAAP Earnings per Share(EPS) of -11.15. The EPS decreased by -173.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.07% | ||
| ROE | -806.53% | ||
| Debt/Equity | 3.84 |
ASLN Forecast & Estimates
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
For the next year, analysts expect an EPS growth of 58.45% and a revenue growth -100% for ASLN